All In Biotech

Drug Trial Radar · NCT02052596

Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older

Last checked: Nov 20, 2026Latest source record: Apr 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 935 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

935

Actual

Start

Feb 7, 2014

Primary completion

Jun 16, 2015

Study completion Apr 21, 2016

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 3, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the Boostrix® vaccine in adults aged 50 years or older compared to administration of vaccines separately.

Conditions

  • Herpes Zoster

Interventions

  • Herpes Zoster vaccine GSK 1437173ABiological

    2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.

  • BoostrixBiological

    1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE) in GSK1437173A GroupTime frame: At 1 month post-Dose 2 (Month 3)
  2. Antibody Concentrations Against Glycoprotein E (Anti-gE)Time frame: At 1 month post-Dose 2 (Month 3 for GSK1437173A Group adn Month 5 for Control Group)
  3. Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) AntigensTime frame: At 1 month post-Dose 1 (Month 1)
  4. Antibody Concentrations Against Diphteria (Anti-D) and Tetanus (Anti-T) AntigensTime frame: At 1 month post-Dose 1 (Month 1)

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Stockbridge, Georgia

  • GSK Investigational Site

    Meridian, Idaho

  • GSK Investigational Site

    Lewiston, Maine

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Salisbury, North Carolina

  • GSK Investigational Site

    Uniontown, Pennsylvania

  • GSK Investigational Site

    Warwick, Rhode Island

  • GSK Investigational Site

    Greer, South Carolina

  • GSK Investigational Site

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.